NanoBioFab blends nanotechnology with artificial intelligence to create innovative solutions for early infection detection and personalized healthcare. Founded by Dr. Xiaonao Liu, this medtech company is revolutionizing the medical industry with its AI-driven smart sensors and high-throughput 3D nano-printing technology. NanoBioFab is on a journey fueled by personal motivation, cutting-edge technology, and a relentless drive for innovation.
From Personal Tragedy to Technological Triumph
NanoBioFab’s inception is rooted in a deeply”personal story. Dr. Liu’s father-in-law succumbed to leukemia, a tragedy that ignited her and her husband’s desire to combine their expertise in nanosensors and AI technology to evolve early disease detection technology.
Originally, the mission was to focus on cancer, but the complexities of cancer detection prompted a pivot. The company’s first target became the early detection of infections in chronic and acute wounds, a decision driven by both technological feasibility and urgent medical need. Dr. Liu shares: “This pivot has allowed us to develop non-invasive devices that provide continuous, real-time monitoring of bacterial growth, enabling early intervention and significantly improving patient outcomes.
Innovative Technology at the Core
NanoBioFab’s breakthrough lies in its unique blend of nanotechnology and AI. The company employs patented technology to produce ultra-fast, high-throughput 3D nano-prints and screen nanosensors capable of detecting minute amounts of gases from the skin and the breath. This technology is poised to transform telemedicine and personalized healthcare, particularly with the advent of 5G connectivity.
“Our AI-powered high-throughput experimentation in nanosensors shortens the time to market and enhances the quality of R&D in all phases of sensor and process development,” Dr. Liu explains. “We support our customers from idea generation to sensor development with dedicated project teams, state-of-the-art technology solutions, and integrated analytical software.”
The high-throughput 3D nano-printing synthesis and screening platform NanoBioFab has developed is the fastest large-scale sensor R&D technology in the world. It drastically reduces R&D time from several years to mere months, offering a significant competitive edge in the medical and defense markets. The platform allows for the creation and rapid screening of hundreds to thousands of unique materials, streamlining the experimental process and reducing personnel costs.
Real-World Applications and Impact
One of NanoBioFab’s flagship products, WoundSentry, exemplifies the company’s innovative spirit. This product integrates nanosensors into smart bandages and dressings to continuously monitor bacterial growth and track antibiotic treatment effectiveness. This technology is not only revolutionary but essential for high-risk patients, particularly in military and medical settings.
“WoundSentry can be compatible with various types of wound dressings and provides real-time data on bacterial growth,” says Dr. Liu. “This capability is crucial in preventing infections and ensuring timely and effective treatment.”
The company’s innovative solutions have garnered significant attention and investment, including a $3.3 million contract from the Defense Health Agency. This funding underscores the critical need for advanced infection detection technologies in civilian and military healthcare.
A Team of Visionaries
NanoBioFab’s success is driven by a diverse team of experts, including material scientists, sensor engineers, microbiologists, AI experts, and medical device specialists. This multidisciplinary approach is fundamental to smart sensors’ high-throughput development and successful deployment in various applications, especially in wound care.
“We have eight PhDs on our team, each bringing unique expertise in chemistry, chemical engineering, microbiology, and AI,” Dr. Liu notes. “Our team’s diversity in background and thought is our strength, enabling us to tackle complex challenges and drive innovation forward.”
Its leadership team comprises Dr. Liu, Dr. Ruoting Yang (Co-Founder and CIO), Dr. Robert Hopkins (Chief Medical Officer), Dr. Christopher Steele (Business Development Officer), and Carrie Zhang (Marketing Officer). Its technical team comprises Dr. Taejun Ko (Head of Project Management), Dr. Averell Gnatt (Senior Biosensor Scientist), Dr. Deyu Liu (Director of Sensor R&D), Dr. Yifeng Shi (Senior NanoMaterial Scientist), Buyu Yeh (Senior Development Scientist), and Daniel Watson (Software and Data Analysis Engineer).
Looking Ahead: A Vision for the Future
Dr. Liu envisions a future where NanoBioFab’s technologies become next-gen medical diagnostics tools. The goal is to obtain FDA clearance for their products within the next two to three years and significantly impact wound care and infection management. “My goal is within ten years, Nanobiofab will become a leader in the next-generation diagnostic market,” adds Dr. Liu. “The potential to impact millions of patients globally is what drives us every day.”
NanoBioFab’s journey is a testament to the power of innovation, resilience, and the relentless pursuit of a vision. From a personal tragedy to groundbreaking technological advancements, Dr. Liu and her team are redefining what’s possible in the realm of medical sensing technology. Their story is not just one of scientific achievement but of hope, determination, and the unwavering belief that technology can change lives.
